Please assess the completion status of the following clinical trial:

Trial Title: Neurogenic Inflammation in Diabetes

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with type 2 diabetes with and without polyneuropathy.~* Patients with type 2 diabetes with a history of Charcot's disease.~* Healthy controls.~* Signed informed consent.~Exclusion Criteria:~* Peripheral arterial disease: toe pressure \< 70 mm Hg and/or transcutaneous oxygen tension \< 40 mm Hg and/or claudication.~* Renal insufficiency: MDRD creatinin clearance \< 30 ml/min.~* Systemic disease such as vasculitis or rheumatoid arthritis.~* Malignancy.~* (Diabetic) foot ulcer.~* Gout.~* Bacterial infection of an extremity.~* Skin condition of the dorsal aspect of the foot or the medial side of the upper arm.~* Bleeding disorder such as hemophilia.~* Use of medication for asthma.~* Impaired immunity such as in HIV/AIDS.~* Capillary blood glucose \< 3 mmol/l or \> 20 mmol/l at the time of the study.~* Peripheral oedema.~* Vaccination in the two months prior to study inclusion.~* Chemotherapy or radiation therapy in the twelve months prior to study inclusion.~* Surgery in the two months prior to study inclusion.~* Previous adverse reaction to Candida albicans antigen.~* Acute infection at the time of the study or in the month prior to study inclusion.~* Transfusion in the two months prior to study inclusion.~* Use of immunosuppressants in the two months prior to study inclusion.~* Pregnancy or breastfeeding.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Healthy controls (Type: EXPERIMENTAL): None
- Diabetes (Type: EXPERIMENTAL): Patients with diabetes mellitus without polyneuropathy.
- Polyneuropathy (Type: EXPERIMENTAL): Patients with diabetes and polyneuropathy.

Based on this trial design, predict the completion outcome and termination type (if applicable).